Identification of novel therapeutic targets for polyglutamine diseases that target mitochondrial fragmentation

Abstract

Huntington’s disease (HD) is one of at least nine polyglutamine diseases caused by a tri-nucleotide CAG repeat expansion, all of which lead to age‐onset neurodegeneration. Mitochondrial dynamics and function are disrupted in HD and other polyglutamine diseases. While multiple studies have found beneficial effects from decreasing mitochondrial fragmentation in HD models by disrupting the mitochondrial fission protein DRP1, disrupting DRP1 can also have detrimental con-sequences in wild‐type animals and HD models. In this work, we examine the effect of decreasing mitochondrial fragmentation in a neuronal C. elegans model of polyglutamine toxicity called Neur‐ 67Q. We find that Neur‐67Q worms exhibit mitochondrial fragmentation in GABAergic neurons and decreased mitochondrial function. Disruption of drp‐1 eliminates differences in mitochondrial morphology and rescues deficits in both movement and longevity in Neur‐67Q worms. In testing twenty‐four RNA interference (RNAi) clones that decrease mitochondrial fragmentation, we identified eleven clones—each targeting a different gene—that increase movement and extend lifespan in Neur‐67Q worms. Overall, we show that decreasing mitochondrial fragmentation may be an ef-fective approach to treating polyglutamine diseases and we identify multiple novel genetic targets that circumvent the potential negative side effects of disrupting the primary mitochondrial fission gene drp‐1.